Drugs / INF904
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06555328 | Jan 2025 → Jan 2026 | chronic idiopathic urticaria, hidradenitis suppurativa | InflaRx GmbH | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-09-03 | InflaRx GmbH | Results InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases inflarx.de ↗ |
| 2024-01-04 | InflaRx GmbH | Results InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 inflarx.de ↗ |
| 2023-09-11 | InflaRx GmbH | Results InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 inflarx.de ↗
In the SAD part of the study, INF904 demonstrated an excellent safety and tolerability profile as well as a very favorable pharmacokinetic (PK) and pharmacodynamic (PD) profile, confirming INF904´s best-in-class potential. |
All press releases naming this drug 10 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INF904 | “Phase 2a Open-Label Basket Study to Evaluate Safety and Pharmacokinetics of INF904, an Oral C5aR1 Inhibitor, in Subjects With Moderate to Severe Chronic Spontaneous Urticaria...” NCT06555328 ↗ |
| Action | Inhibit | “an Oral C5aR1 Inhibitor” NCT06555328 ↗ |
| Route | Oral | “an Oral C5aR1 Inhibitor” NCT06555328 ↗ |
| Target | C5AR1 | “an Oral C5aR1 Inhibitor” NCT06555328 ↗ |